Publications by authors named "Fabiola Landi"

Background: Virus-specific CD4 and CD8 T lymphocytes from HLA-matched donors are effective for treatment and prophylaxis of viral infections in immune-compromised recipients of hematopoietic stem cell transplant recipients. Adoptive immune reconstitution is based on selection of specific T cells or on generation of specific T-cell lines from the graft donor. Unfortunately, the graft donor is not always immune to the relevant pathogen or the graft donor may not be available (registry-derived or cord blood donors).

View Article and Find Full Text PDF

Monitoring of antigen-specific T-cell responses is valuable in numerous conditions that include infectious diseases, vaccinations, and opportunistic infections associated with acquired or congenital immune defects. A variety of assays that make use of peripheral lymphocytes to test activation markers, T-cell receptor expression, or functional responses are currently available. The last group of assays calls for large numbers of functional lymphocytes.

View Article and Find Full Text PDF

Background: Hematopoietic stem cell transplantation is commonly used to treat several oncohematologic diseases. The autologous hematopoietic progenitor cells collected through apheresis (HPC-A) must be cryopreserved and stored before use in vivo. Cell processing that precedes cryopreservation of HPC-A includes volume reduction aimed at reducing the amount of dimethyl sulfoxide used, as well as storage space.

View Article and Find Full Text PDF

T regulatory cells are fundamental in the maintenance of immune homeostasis and self-tolerance. Experimental models suggest the existence of two functional types of T(reg) cells designated naturally occurring and induced. Interest in T(reg) cells increased with evidence from experimental mouse and human models demonstrating that the immunosuppressive potential of these cells can be utilized in the treatment of various pathological conditions.

View Article and Find Full Text PDF
Article Synopsis
  • Umbilical cord blood (UCB) is a promising alternative for stem cell transplants, but its limited cell quantity makes it suitable primarily for low-weight patients.
  • This study analyzed the outcomes of thawing 40 UCB units for patients with various blood disorders, assessing the effectiveness of the Rubinstein method of cellular manipulation before grafting.
  • Results showed a high mean recovery rate of nucleated cells and good viability post-thawing, confirming the technique's efficiency and adherence to shipping protocols.
View Article and Find Full Text PDF

Background Aims: Immunomagnetic CD34(+) cell selection (ICS) is utilized in autologous and allogeneic transplants. In the first case it is used to reduce the neoplastic contamination of concentrates, while in the second case it is needed to carry out a T-depletion of cell concentrates in order to reduce the incidence of graft-versus-host disease (GvHD) in patients who have undergone haplo-identical transplants.

Methods: The efficacy of CliniMACS technology, after reduction of platelet contamination, incubation of monoclonal antibodies (MAb) and successive washings of concentrates, performed in 16 ICS using the standard method without reducing platelet content, was compared with the use of the automated system CytoMate, which was carried out in 46 ICS.

View Article and Find Full Text PDF

Background: Immunomagnetic selection of peripheral blood progenitor cells (PBPCs) in patients with tumoral infiltration in marrow makes it possible to reduce contamination of cellular concentrates, but this procedure cannot always be used, mainly because of the low cellular count in apheresis concentrates.

Study Design And Methods: In this case two cellular concentrates taken separately at two different times were selected and cryopreserved; they were thawed with an automatic instrument.

Results: After manipulation, a selected concentrate containing 24.

View Article and Find Full Text PDF
Article Synopsis
  • - The study investigated whether short-term sublingual immunotherapy (SLIT) can effectively reduce asthma development in children aged 5 to 14 with hay fever, comparing it to traditional subcutaneous immunotherapy.
  • - Conducted among 113 participants across 6 pediatric allergy centers in Italy, the study showed that those receiving SLIT required less medication and had lower symptom scores over three years.
  • - Findings revealed that children on SLIT had a significantly lower rate of developing asthma (3.8 times less) compared to those receiving only symptomatic treatment, indicating SLIT's effectiveness in managing hay fever and preventing asthma.
View Article and Find Full Text PDF